Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for XNCR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 85.12M
March 31, 2026 26.68M
December 31, 2025 72.90M
September 30, 2025 14.67M
June 30, 2025 40.48M
March 31, 2025 11.94M
December 31, 2024 57.25M
September 30, 2024 -163.46M
June 30, 2024 66.02M
March 31, 2024 32.32M
December 31, 2023 -202.63M
September 30, 2023 45.33M
June 30, 2023 -1.405M
March 31, 2023 48.14M
December 31, 2022 24.55M
September 30, 2022 3.125M
June 30, 2022 -75.64M
March 31, 2022 -71.76M
December 31, 2021 7.86M
September 30, 2021 -38.85M
June 30, 2021 -53.31M
March 31, 2021 38.05M
December 31, 2020 78.78M
September 30, 2020 -50.56M
June 30, 2020 59.41M
Date Value
March 31, 2020 12.56M
December 31, 2019 15.73M
September 30, 2019 22.06M
June 30, 2019 -102.43M
March 31, 2019 13.67M
December 31, 2018 6.866M
September 30, 2018 5.862M
June 30, 2018 -190.17M
March 31, 2018 12.67M
December 31, 2017 8.939M
September 30, 2017 4.933M
June 30, 2017 9.439M
March 31, 2017 8.553M
December 31, 2016 -104.27M
September 30, 2016 -127.66M
June 30, 2016 8.623M
March 31, 2016 9.66M
December 31, 2015 -41.69M
September 30, 2015 6.933M
June 30, 2015 -101.29M
March 31, 2015 -49.06M
December 31, 2014 -0.587M
September 30, 2014 -0.573M
June 30, 2014 -0.675M
March 31, 2014 -0.448M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
UroGen Pharma Ltd. 1.185M
MeiraGTx Holdings Plc -23.63M
Regeneron Pharmaceuticals, Inc. -92.70M
Ironwood Pharmaceuticals, Inc. 0.00
MacroGenics, Inc. 27.96M